Halozyme Therapeutics, Inc. (NASDAQ:HALO) will be presenting at the JMP Securities 2014 Healthcare Conference in New York, NY, on Tuesday, June 24, 2014 at 2:30 p.m. Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock opened today at $10.17 and is currently trading at $10.24. The stock showed a positive weekly performance of 0.99%.
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced that the Company is set to join the Russell Microcap® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) stock opened at $2.48, in current trading session and currently is at $2.59, by gaining 2.78%. The 52 week range of $0.83 – $3.65. Company’s market capitalization is 173.97 million.
Rexahn Pharmaceuticals Inc. (NYSE:RNN) Director Chang Ho Ahn unloaded 136,193 shares of the stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $0.99, for a total transaction of $134,831.07. Following the completion of the transaction, the director now directly owns 6,813,924 shares of the company’s stock, valued at approximately $6,745,785. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock is currently trading at $0.873. The EPS of the stock is -0.15. Company’s market capitalization is 155.32 million.
Inovio Pharma Inc. (NYSEMKT:INO) has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer. INO-3112 is a combination of Inovio’s lead active immunotherapy product, VGX-3100, and its proprietary immune activator expressing interleukin-12 (IL-12). VGX-3100 is currently being evaluated in a randomized phase II efficacy trial for the treatment of high grade cervical dysplasia (pre-cancer). Inovio Pharmaceuticals Inc. (NYSEMKT:INO) stock opened the session at $9.20, and now is at $9.28. The 52 week range of the Inovio Pharmaceuticals Inc. (NYSEMKT:INO) stock remained $2.64 – $15.80 and the day range was $9.16 – $9.38.
Cubist Pharmaceuticals Inc. (NASDAQ:CBST) moved a step closer towards achieving its objective of having four antibiotics in the market by 2015 when the FDA approved Sivextro (200 mg: once daily for six days). Sivextro, cleared by the FDA for treating adults suffering from acute bacterial skin and skin structure infections (ABSSSI), becomes the third approved antibiotic in Cubist’s portfolio, after Cubicin and Dificid. Cubist Pharmaceuticals Inc. (NASDAQ:CBST) stock opened today at $72.99 and is currently trading at $72.79. The stock showed a positive weekly performance of 5.14%.